The company discovers, develops, and commercializes therapies targeting immunology, neuroscience, and oncology. Its pipeline spans multiple clinical and preclinical stage candidates, with the most advanced programs in Phase 3 trials. These include troriluzole for neurological and neuropsychiatric disorders, taldefgrobep alfa for spinal muscular atrophy and obesity, and BHV-7000 for focal and generalized epilepsy and major depressive disorder. Earlier-stage programs address conditions including migraines, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, and various cancers.
The company operates strategic partnerships with research institutions including Yale University and Katholieke Universiteit Leuven, as well as pharmaceutical and biotechnology partners such as Bristol Myers Squibb, Merus N.V., and GeneQuantum Healthcare. These partnerships extend the company's research capabilities and geographic reach, particularly in Asia through agreements with Hangzhou Highlightll Pharmaceutical and GeneQuantum Healthcare.
Biohaven is headquartered in New Haven, Connecticut, with approximately 256 full-time employees. The company was incorporated in the British Virgin Islands and listed on the New York Stock Exchange. Given its pre-commercialization stage pipeline and clinical development focus, revenue generation remains limited to partnership agreements and milestone-based payments rather than product sales.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-6.86 | $-6.86 | +26.1% | |
| 2024 | $-9.28 | $-9.28 | -62.0% | |
| 2023 | $-5.73 | $-5.73 | +55.1% | |
| 2022 | $-12.75 | $-12.75 | — |